trending Market Intelligence /marketintelligence/en/news-insights/trending/-qq6Q5FKfP7uhOUrdZvObA2 content esgSubNav
In This List

Everstone to invest US$50M in KKR-backed Slayback Pharma

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Podcast

Street Talk Episode 87

Blog

A New Dawn for European Bank M&A Top 5 Trends

Blog

Insight Weekly: US banks' loan growth; record share buybacks; utility M&A outlook


Everstone to invest US$50M in KKR-backed Slayback Pharma

Asia-focused private equity firm Everstone Capital Asia Pte Ltd. agreed to invest up to US$50 million in a series B funding round in KKR & Co. Inc.-backed pharmaceutical company Slayback Pharma LLC.

Along with the investment, Everstone's managing directors Arjun Oberoi and Puncham Mukim will join Slayback's board.

The capital will be used to expand and accelerate Slayback's differentiated line of pharmaceutical products.

KKR invested US$60 million in Slayback in December 2016.